VCNX - Vaccinex Inc Stock Price, Fair Value and News

6.05USD-0.13 (-2.10%)Market Closed

Market Summary

USD6.05-0.13

Market Closed

-2.10%

VCNX Stock Price

View Fullscreen

VCNX RSI Chart

VCNX Valuation

Market Cap

7.5M

Price/Earnings (Trailing)

-0.37

Price/Sales (Trailing)

13.07

EV/EBITDA

-0.29

Price/Free Cashflow

-0.43

VCNX Price/Sales (Trailing)

VCNX Profitability

Operating Margin

98.25%

EBT Margin

-3561.40%

Return on Equity

880.48%

Return on Assets

-557.73%

Free Cashflow Yield

-232.19%

VCNX Fundamentals

VCNX Revenue

Revenue (TTM)

570.0K

Rev. Growth (Yr)

-100%

Rev. Growth (Qtr)

-100%

VCNX Earnings

Earnings (TTM)

-20.3M

Earnings Growth (Yr)

34.68%

Earnings Growth (Qtr)

32.47%

Breaking Down VCNX Revenue

Last 7 days

3.8%

Last 30 days

-10.4%

Last 90 days

-28.0%

Trailing 12 Months

-91.8%

How does VCNX drawdown profile look like?

VCNX Financial Health

Current Ratio

0.57

Debt/Equity

-0.01

Debt/Cashflow

-662.85

VCNX Investor Care

Shares Dilution (1Y)

371.48%

Diluted EPS (TTM)

-44.45

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	825.0K	825.0K	795.0K	570.0K
2022	0	0	100.0K	325.0K
2021	1.5M	1.5M	900.0K	900.0K
2020	0	0	1.1M	1.0M
2019	612.0K	511.0K	717.0K	523.0K
2018	248.5K	407.0K	565.5K	724.0K
2017	0	0	0	90.0K

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Vaccinex Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Apr 19, 2024	friedberg albert	bought	1,333	4.73	282	-
Mar 28, 2024	friedberg albert	acquired	799,999	7.77	102,960	-
Mar 28, 2024	zauderer maurice	acquired	300,000	7.77	38,610	president and ceo
Feb 08, 2024	zauderer maurice	acquired	300,000	0.725	413,793	president and ceo
Feb 08, 2024	friedberg albert	acquired	1,200,000	0.725	1,655,170	-
Dec 26, 2023	van strydonck, gerald e.	sold	-2,267	0.72	-3,149	-
Dec 08, 2023	van strydonck, gerald e.	sold	-893	0.67	-1,334	-
Oct 04, 2023	zauderer maurice	bought	4,865	0.973	5,000	president and ceo
Oct 03, 2023	zauderer maurice	bought	4,650	0.93	5,000	president and ceo
Oct 03, 2023	zauderer maurice	bought	500,000	1.00	500,000	president and ceo

Which funds bought or sold VCNX recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 01, 2024	CONCOURSE FINANCIAL GROUP SECURITIES, INC.	sold off	-	-	-	-%
May 01, 2024	CONCOURSE FINANCIAL GROUP SECURITIES, INC.	sold off	-	-	-	-%
Apr 18, 2024	Capital Advisors, Ltd. LLC	new	-	-	-	-%
Mar 11, 2024	VANGUARD GROUP INC	unchanged	-	-22,433	32,057	-%
Feb 14, 2024	GROUP ONE TRADING, L.P.	unchanged	-	-426	609	-%
Feb 14, 2024	BANK OF AMERICA CORP /DE/	reduced	-94.03	-73.00	3.00	-%
Feb 14, 2024	MILLENNIUM MANAGEMENT LLC	sold off	-100	-15,545	-	-%
Feb 14, 2024	TWO SIGMA INVESTMENTS, LP	new	-	10,743	10,743	-%
Feb 14, 2024	Royal Bank of Canada	unchanged	-	-	-	-%
Feb 13, 2024	XTX Topco Ltd	new	-	7,803	7,803	-%

Are Funds Buying or Selling VCNX?

Are funds buying VCNX calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own VCNX

No. of Funds

Unveiling Vaccinex Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 13, 2024	fcmi parent co.	39.2%	6,405,475	SC 13D/A
Feb 12, 2024	zauderer maurice	14.4%	2,500,771	SC 13D/A
Feb 09, 2024	point72 asset management, l.p.	9.9%	5,793,452	SC 13G
Feb 07, 2024	hirschman orin	9.9%	1,247,061	SC 13G/A
Oct 18, 2023	fcmi parent co.	38.02%	4,750,303	SC 13D/A
Oct 12, 2023	zauderer maurice	11.8%	1,534,324	SC 13D/A
Oct 11, 2023	hirschman orin	9.9%	1,233,382	SC 13G
Sep 26, 2023	zauderer maurice	10.8%	524,324	SC 13D/A
May 25, 2023	fcmi parent co.	40.2%	26,254,537	SC 13D/A
Apr 05, 2023	fcmi parent co.	35.6%	19,542,985	SC 13D/A

Recent SEC filings of Vaccinex Inc

View All Filings

Date Filed	Form Type	Document
Apr 26, 2024	S-3	S-3
Apr 25, 2024	10-K/A	Annual Report
Apr 22, 2024	4	Insider Trading
Apr 16, 2024	EFFECT	EFFECT
Apr 16, 2024	424B3	Prospectus Filed
Apr 12, 2024	D	D
Apr 12, 2024	D	D
Apr 12, 2024	D	D
Apr 12, 2024	8-K	Current Report
Apr 02, 2024	10-K	Annual Report

Peers (Alternatives to Vaccinex Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	47.9B	6.8B	23.52%	-6.94%	-8.03	7	-64.45%	-224.75%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	19.3B	2.0B	0.99%	-25.83%	-58.02	9.62	75.20%	68.82%
BMRN	15.7B	2.5B	-4.94%	-13.58%	76.24	6.34	13.74%	186.89%
INCY	12.1B	3.8B	-2.80%	-18.78%	16.19	3.2	8.58%	129.81%
MID-CAP
APLS	5.7B	396.6M	-16.72%	-43.78%	-10.82	14.42	425.83%	18.94%
BBIO	5.2B	107.9M	-4.79%	106.15%	-9.53	48.09	54.84%	-28.31%
AXSM	3.5B	270.6M	1.74%	5.10%	-14.81	13.09	440.80%	-27.84%
ARWR	3.0B	240.7M	-7.74%	-39.00%	-10.2	12.18	-1.03%	-92.09%
ACAD	2.8B	726.4M	-7.55%	-20.97%	-45.79	3.86	40.45%	71.62%
SMALL-CAP
CPRX	1.7B	398.2M	-4.91%	-11.58%	24.31	4.36	85.90%	-14.05%
NVAX	687.2M	983.7M	8.15%	-35.14%	-1.26	0.7	-50.36%	17.16%
CRBP	408.0M	881.7K	0.99%	345.87%	-9.15	466.16	-77.61%	-5.33%
INO	282.8M	4.9M	-1.94%	21.49%	-2.09	58.11	-54.97%	51.71%
IBIO	6.9M	2.1M	-32.65%	86.79%	-0.25	2.14	-13.45%	66.37%

Vaccinex Inc News

Latest updates

Vaccinex Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4	2018Q3	2018Q2	2018Q1	2017Q4
Revenue	-100.0%	-	20,000	-	550,000	225,000	50,000	-	50,000	-	850,000	-	625,000	-	404,000	25,000	94,000	194,000	198,000	126,000	206,000	-
Cost Of Revenue	-	-	-	-	-	-	-	-	-	-	-	-	2,000	-	8,000	16,000	175,000	301,000	246,000	246,000	240,000	-
Costs and Expenses	-14.8%	4,988,000	5,854,000	7,077,000	5,536,000	5,344,000	4,842,000	5,518,000	5,113,000	5,669,000	7,090,000	6,089,000	9,208,000	6,339,000	8,082,000	8,883,000	9,234,000	8,755,000	6,652,000	6,683,000	5,915,000	-
S&GA Expenses	-100.0%	-	1,499,000	2,027,000	1,724,000	1,603,000	1,413,000	1,564,000	1,484,000	1,605,000	1,577,000	1,840,000	1,872,000	1,928,000	1,531,000	1,563,000	1,647,000	1,381,000	1,092,000	925,000	1,221,000	-
R&D Expenses	-22.9%	3,357,000	4,355,000	5,050,000	3,812,000	3,741,000	3,429,000	3,954,000	3,629,000	4,064,000	5,513,000	4,249,000	7,334,000	4,411,000	6,543,000	7,304,000	7,412,000	7,073,000	5,314,000	5,512,000	4,454,000	-
EBITDA Margin	-29.5%	-35.61	-27.50	-26.27	-24.20	-60.28	-191	-23.78	-25.37	-17.86	-18.42	-27.26	-26.79	-	-	-	-	-	-	-	-	-
Interest Expenses	-100.0%	-	500	-	-	-500	1,000	-16,000	142,000	351,000	332,000	339,000	148,000	-	-	-	-	-	44,000	81,000	267,000	-
Income Taxes	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Earnings Before Taxes	31.5%	-3,366,000	-4,912,000	-7,060,000	-4,962,000	-5,063,000	-4,759,000	-4,631,000	-5,206,000	-5,969,000	-6,574,000	-6,446,000	-8,754,000	-6,326,000	-7,642,000	-8,828,000	-9,067,000	-8,449,000	-6,599,000	-6,608,000	-7,862,000	-
EBT Margin	-28.7%	-35.61	-27.67	-26.48	-24.44	-60.92	-193	-24.87	-26.88	-18.81	-19.17	-28.04	-27.26	-	-	-	-	-	-	-	-	-
Net Income	32.5%	-3,317,000	-4,912,000	-7,060,000	-4,962,000	-5,078,000	-4,759,000	-4,631,000	-5,206,000	-5,969,000	-6,574,000	-6,446,000	-8,754,000	-6,326,000	-7,642,000	-8,828,000	-9,067,000	-8,449,000	-6,599,000	-6,608,000	-7,862,000	-
Net Income Margin	-28.3%	-35.53	-27.69	-26.50	-24.46	-60.97	-193	-24.87	-26.88	-18.81	-19.17	-28.04	-27.26	-	-	-	-	-	-	-	-	-
Free Cashflow	-13.7%	-3,592,000	-3,160,000	-5,460,000	-5,089,000	-4,623,000	-4,195,000	-5,145,000	-6,069,000	-6,981,000	-7,113,000	-6,381,000	-9,344,000	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Balance Sheet																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	41.9%	3,631	2,558	3,085	4,895	7,977	8,612	12,572	18,121	9,843	15,189	23,789	30,684	11,702	18,725	3,099	4,881	4,604	10,810	7,121	13,294	22,028
Current Assets	51.8%	3,349	2,206	2,679	4,418	7,478	8,025	12,261	17,766	9,405	14,862	23,442	30,313	11,286	18,237	2,574	4,269	4,010	10,309	6,566	12,750	21,424
Cash Equivalents	1108.7%	1,535	127	1,908	3,323	6,391	7,186	11,400	16,803	8,589	13,741	22,385	29,389	10,596	17,092	526	2,491	2,776	8,578	5,279	5,279	5,618
Net PPE	-17.1%	136	164	177	207	189	236	254	256	297	327	347	371	416	488	525	612	594	501	555	544	604
Liabilities	-7.5%	5,942	6,427	3,508	2,495	2,784	2,294	1,629	1,933	2,431	3,299	6,849	7,903	14,314	14,961	8,677	6,620	6,878	6,896	9,501	6,959	6,686
Current Liabilities	-7.0%	5,916	6,362	3,383	2,310	2,537	1,987	1,491	1,777	2,256	2,165	5,715	6,769	13,180	13,827	7,543	-	6,878	-	-	-	6,686
Long Term Debt	-40.9%	26.00	44.00	63.00	82.00	101	119	138	156	175	1,134	1,134	1,134	1,134	1,134	1,134	-	-	-	-	-	-
LT Debt, Current	0%	75.00	75.00	75.00	75.00	74.00	74.00	74.00	74.00	74.00	-	-	-	-	-	-	-	-	-	-	-	-
LT Debt, Non Current	-100.0%	-	44.00	63.00	82.00	101	119	138	156	175	1,134	1,134	1,134	1,134	1,134	1,134	-	-	-	-	-	-
Shareholder's Equity	-Infinity%	-2,300	-	-	2,400	5,193	6,318	10,943	16,188	7,412	11,890	16,940	22,781	-	3,765	-	-	-	3,914	-	6,335	15,342
Retained Earnings	-1.0%	-339,900	-336,610	-331,698	-324,638	-319,676	-314,598	-309,839	-304,500	-299,900	-295,230	-290,024	-284,055	-277,481	-271,034	-262,280	-255,779	-248,630	-242,304	-234,662	-225,834	-216,767
Additional Paid-In Capital	1.5%	337,627	332,752	331,279	327,044	324,880	320,923	320,789	320,651	307,281	307,128	306,972	284,881	250,914	250,843	232,748	230,086	222,403	222,265	208,329	208,216	208,156
Shares Outstanding	157.2%	893	347	313	261	238	203	194	185	147	147	136	120	107	-	-	-	-	-	-	-	-
Minority Interest	-	-	-	-	-	-	-	-	-	-	-	-	21,963	23,963	23,963	23,963	23,963	23,963	23,963	23,963	23,963	23,963
Float	-	-	-	10,420	-	-	-	25,255	-	-	-	47,747	-	-	-	23,671	-	-	-	23,013	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	-14.3%	-3,592	-3,142	-5,460	-5,040	-4,625	-4,146	-5,333	-4,996	-5,145	-6,059	-6,982	-7,114	-6,382	-9,307	-5,448	-7,510	-5,803	-10,490	-5,946	-8,476	-7,557
Share Based Compensation	-9.6%	104	115	126	129	132	134	138	141	153	156	128	104	71.00	91.00	366	204	138	137	113	60.00	46.00
Cashflow From Investing	100.0%	-	-18.00	-	-49.00	2.00	-49.00	-	-	-	-10.00	-	-	1.00	-37.00	-	-254	-	-10.00	2,283	11,800	1,917
Cashflow From Financing	275.4%	5,000	1,332	4,092	2,021	3,802	-19.00	-18.00	13,210	-9.00	-2,575	-	25,907	-115	25,910	3,483	7,479	-	-	-	-	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

VCNX Income Statement

2023-12-31

Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Income Statement [Abstract]
Revenue	$ 570	$ 275
Costs and expenses:
Research and development	16,574	13,979
General and administrative	6,881	6,202
Total costs and expenses	23,455	20,181
Loss from operations	(22,885)	(19,906)
Interest expense	(1)	(2)
Financing costs - warrant liabilities	(383)
Change in fair value of warrant liabilities	2,106
Other income (expense), net	912	93
Loss before provision for income taxes	(20,251)	(19,815)
Provision for income taxes	0	0
Net loss attributable to Vaccinex, Inc. common stockholders	(20,251)	(19,815)
Comprehensive loss	$ (20,251)	$ (19,815)
Net loss per share attributable to Vaccinex, Inc. common stockholders, basic	$ (43.68)	$ (98.05)
Net loss per share attributable to Vaccinex, Inc. common stockholders, diluted	$ (43.68)	$ (98.05)
Weighted-average shares used in computing net loss per share attributable to Vaccinex, Inc. common stockholders, basic	463,653	202,082
Weighted-average shares used in computing net loss per share attributable toVaccinex, Inc. common stockholders, diluted	463,653	202,082

VCNX Balance Sheet

2023-12-31

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 1,535	$ 6,391
Accounts receivable	961	175
Prepaid expenses and other current assets	853	912
Total current assets	3,349	7,478
Property and equipment, net	136	189
Operating lease right-of-use asset	146	310
TOTAL ASSETS	3,631	7,977
Current liabilities:
Accounts payable	2,039	1,518
Accrued expenses	1,242	781
Deferred revenue	63
Current portion of long-term debt	75	74
Operating lease liability	146	164
Warrant liability	2,351
Total current liabilities	5,916	2,537
Long-term debt	26	101
Operating lease liability, net of current portion		146
TOTAL LIABILITIES	5,942	2,784
Commitments and contingencies (Note 6)
Stockholders’ equity (deficit):
Common stock, par value of $0.0001 per share; 100,000,000 shares authorized as of December 31, 2023, and December 31, 2022; 892,622 and 237,532	0	0
Additional paid-in capital	337,627	324,880
Treasury stock, at cost; 5 shares of common stock as of December 31, 2023 and December 31, 2022, respectively	(11)	(11)
Accumulated deficit	(339,927)	(319,676)
TOTAL STOCKHOLDERS' EQUITY/(DEFICIT)	(2,311)	5,193
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY	$ 3,631	$ 7,977

About Vaccinex Inc

Vaccinex, Inc., a clinical-stage biotechnology company, engages in the discovery and development of targeted biotherapeutics to treat cancer, neurodegenerative diseases, and autoimmune disorders. The company's lead drug candidate, pepinemab, a humanized monoclonal antibody that binds and blocks the activity of SEMA4D. Its Pepinemab is being evaluated in a Phase 1b/2 study in recurrent or metastatic head and neck cancer and in a Phase 1/2a study in Alzheimer's Disease, with ongoing exploration of potential Phase 3 development in Huntington's disease. It has also developed ActivMAb, an antibody drug discovery platform based on a novel method for complex targets, such as multi-pass membrane receptors or large and diverse libraries of full-length human monoclonal antibodies on the surface of pox viruses. The company was incorporated in 2001 and is headquartered in Rochester, New York.

CEO	Dr. Maurice Zauderer Ph.D.
WEBSITE	vaccinex.com
INDUSTRY	Biotechnology
EMPLOYEES	38

Vaccinex Inc Frequently Asked Questions

What is the ticker symbol for Vaccinex Inc? What does VCNX stand for in stocks?

VCNX is the stock ticker symbol of Vaccinex Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Vaccinex Inc (VCNX)?

As of Fri May 03 2024, market cap of Vaccinex Inc is 7.45 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of VCNX stock?

You can check VCNX's fair value in chart for subscribers.

What is the fair value of VCNX stock?

You can check VCNX's fair value in chart for subscribers. The fair value of Vaccinex Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Vaccinex Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for VCNX so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Vaccinex Inc a good stock to buy?

The fair value guage provides a quick view whether VCNX is over valued or under valued. Whether Vaccinex Inc is cheap or expensive depends on the assumptions which impact Vaccinex Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for VCNX.

What is Vaccinex Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 03 2024, VCNX's PE ratio (Price to Earnings) is -0.37 and Price to Sales (PS) ratio is 13.07. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. VCNX PE ratio will change depending on the future growth rate expectations of investors.